Prediction of Tubulin Inhibitor Sensitivity in Colon Cancer

A 37-gene ColoTubIn signature predicts paclitaxel sensitivity in patient-derived colon cancer models, with low scores linked to increased drug responsiveness.

• Why it matters: Prognostic signatures have not yet translated well into therapy selection, so predictive biomarkers are needed to guide tubulin inhibitor use in colorectal cancer.
• What they did: Using public gene expression datasets, the team built and validated a 37-gene prognostic signature across six clinical cohorts, then tested tubulin inhibitor response to paclitaxel in vitro and in vivo in patient-derived preclinical models.
• The result: ColoTubIn performs comparably to published prognostic signatures across six cohorts without clinical covariates and is linked to the mitotic cell-cycle phase, while low scores identify paclitaxel-sensitive models for potential drug repurposing.

AI summary of the abstract · may contain errors · not medical advice · read the paper.